Table 2.

Adverse events regardless of attribution to MOXR0916 occurring in ≥10% patients overall.

	0.2 to 160 mg		300 mg		600 mg		1,200 mg		All patients
	n = 53		n = 109		n = 6		n = 4		(N = 172)
	Grade		Grade		Grade		Grade		Grade
MedDRA preferred term, n (%)	All	≥3	All	≥3	All	≥3	All	≥3	All	≥3
Patients with ≥1 AE	51 (96)	38 (72)	103 (95)	55 (50)	5 (83)	2 (33)	4 (100)	2 (50)	163 (95)	97 (56)
Fatigue	22 (42)	0	30 (28)	3 (3)	3 (50)	1 (17)	1 (25)	0	56 (33)	4 (2)
Decreased appetite	18 (34)	0	25 (23)	1 (1)	0	0	0	0	43 (25)	1 (1)
Malignant neoplasm progression	17 (32)	17 (32)	24 (22)	24 (22)	1 (17)	1 (17)	0	0	42 (24)	42 (24)
Nausea	13 (25)	0	27 25)	2 (2)	1 (17)	0	1 (25)	0	42 (24)	2 (1)
Constipation	11 (21)	0	26 (24)	2 (2)	1 (17)	0	0	0	38 (22)	2 (1)
Abdominal pain	10 (19)	2 (4)	19 (17)	6 (6)	0	0	0	0	29 (17)	8 (5)
Anemia	10 (19)	7 (13)	17 (16)	6 (6)	0	0	1 (25)	0	28 (16)	13 (8)
Diarrhea	16 (30)	1 (2)	10 (9)	0	1 (17)	0	1 (25)	0	28 (16)	1 (1)
Arthralgia	8 (15)	0	17 (16)	1 (1)	0	0	1 (25)	0	26 (15)	1 (1)
Vomiting	6 (11)	0	19 (17)	0	0	0	1 (25)	0	26 (15)	0
Back pain	6 (11)	0	18 (17)	3 (3)	0	0	1 (25)	0	25 (15)	3 (2)
Dyspnea	8 (15)	2 (4)	16 (15)	1 (1)	0	0	1 (25)	0	25 (15)	3 (2)
Peripheral edema	8 (15)	1 (2)	14 (13)	0	1 (17)	0	2 (50)	0	25 (15)	1 (1)
Cough	9 (17)	0	12 (11)	1 (1)	0	0	0	0	21 (12)	1 (1)
Myalgia	5 (9)	0	13 (12)	0	1 (17)	0	0	0	19 (11)	0
Pyrexia	12 (23)	0	7 (6)	0	0	0	0	0	19 (11)	0